Please login to the form below

Not currently logged in
Email:
Password:

Horizon Pharma

This page shows the latest Horizon Pharma news and features for those working in and with pharma, biotech and healthcare.

Horizon swoops on Raptor to add rare disease products

Horizon swoops on Raptor to add rare disease products

Ireland's Horizon Pharma has bolstered its position in orphan diseases with an $800m agreement to buy Raptor Pharmaceutical of the US. ... Horizon sales are predicted to be around $1bn this year, not including the new additions.

Latest news

  • Allergan CEO takes issue with 'predatory' price increases Allergan CEO takes issue with 'predatory' price increases

    Allergan chief executive Brent Saunders has slammed aggressive price increases in the pharma sector, saying they break an "unwritten social contract". ... Meanwhile other companies - including Valeant, Turing Pharma and Horizon Pharma - have also been

  • PBMs drop Philidor, and Valeant follows suit PBMs drop Philidor, and Valeant follows suit

    The Canadian pharma company's chief executive Michael Pearson said it had taken the decision in the wake of the "newest allegations about activities at Philidor [which] raise additional questions about ... allegations. Meanwhile, other specialty pharma

  • Bio investors react as Clinton tweet pledges pricing crackdown Bio investors react as Clinton tweet pledges pricing crackdown

    The tweet sparked a sell-off for a number of biopharma companies including Biogen, Valeant, Alexion, and Horizon Pharma, down more than 9%. ... Horizon Pharma's fall-off comes partly from its stuttering attempts to acquire Depomed, but the company has

  • Rebuffed Horizon tries to replace Depomed board members Rebuffed Horizon tries to replace Depomed board members

    Rebuffed Horizon tries to replace Depomed board members. But firm says latest deal 'significantly undervalues' Depomed. ... Ireland's Horizon Pharma has made a third offer to acquire Depomed of the US which - like its earlier bids - has been swiftly

  • Horizon launches $3bn hostile bid for Depomed Horizon launches $3bn hostile bid for Depomed

    Ireland's Horizon Pharma has launched a hostile takeover bid for Depomed of the US after being frustrated in its efforts to enter negotiations about combining the two companies. ... Horizon's bid comes as the value of M&A activity in the pharma sector is

More from news
Approximately 3 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Deal Watch September 2016. Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up. ... Upfront $80m plus $830m in milestones [ex S. Korea]. 910. Raptor / Horizon Pharma.

  • Deal Watch October 2015 Deal Watch October 2015

    This was exemplified by the major asset swapping amongst pharma companies of last year. ... More big pharma acquisitions on the horizon? We cannot close this month's Deal Watch without mentioning the reports filtering out near the end of October that

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    For an indepth analysis of these deals, read'Pharma deals during March 2014'. ... Vidara Therapeutics/. Horizon Pharma. Merger/ acquisition. Actimmune (interferon gamma-1b) for CGD and SMO (approved).

  • Pharma deals during March 2014 Pharma deals during March 2014

    US-based Horizon Pharma's acquisition of Irish-based Vidara Therapeutics via a reverse merger for cash and stock comes in at $660m. ... The NewCo will be called Horizon Pharma plc and will be an Irish company to take advantage of the lower corporate tax

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Ziarco appoints Mike Grey to board of directors Ziarco appoints Mike Grey to board of directors

    Grey has served as CEO at numerous biopharma companies, including Auspex Pharma, SGZ Pharma and Trega Biosciences. ... Grey is currently on the boards of BioMarin Pharma, Horizon Pharma, Mirati Therapeutics and Selventa.

  • Oscar Ferenczi joins Grünenthal from Sandoz Oscar Ferenczi joins Grünenthal from Sandoz

    Oscar Ferenczi joins Grünenthal from Sandoz. Will lead German pharma company's Latin American expansion plans. ... and an agreement with US-based Horizon Pharma for the commercialisation of the anti-inflammatory drug Duexis in Latin America.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics